

August 20, 2025

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street, Fort, Mumbai – 400 001

To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir,

Sub: Update on acquisition of securities of O2 Renewable Energy XXIV Private Limited

This is in reference to our prior intimation dated December 18, 2024 regarding acquisition of 34% stake in O2 Renewable Energy XXIV Private Limited, wherein the Company had invested Rs. 1.75 Crores through Equity and Compulsory Convertible Debentures out of the total agreed investment of an amount not exceeding Rs. 1.99 Crores.

The Company is pleased to inform that it has now made the remaining investment of Rs. 0.24 Crores. Pursuant to this, the Company now holds 32.95% stake in O2.

Requisite disclosure required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Schedule III thereof and SEBI Circular no. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023, have already been disclosed in the intimation dated December 18, 2024.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Harish Kuber
Company Secretary & Compliance Officer

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com